Table 5. Estimates of morbidity and mortality in patients undergoing pancreatic resection following neoadjuvant therapy including the 95% confidence interval from the random effect model and number of assessable studies for each group (n).

Group	Morbidity	Mortality
All patients	34.2%[28.3%–40.4%]I2 = 75.8%[68.2%–81.5%](n = 50)	5.3%[4.1%–6.8%]I2 = 29.2%[7%–46.1%](n = 85)
Tumor resectable before treatment (group 1)	26.7%[20.7%–33.3%]I2 = 67.2%[48.8%–79%](n = 22)	3.9%[2.2%–6.0%]I2 = 51.9%[26.9%–68.3%](n = 30)
Tumor non-resectable before treatment (group 2)	39.1%[29.5%–49.1%]I2 = 67.5%[49.8%–78.9%](n = 23)	7.1%[5.1%–9.5%]I2 = 0%[0%–23.4%](n = 43)